Benjamin Levy, MD
Disclosures: Consulting Fee-AstraZeneca-Other_Role-Consultant|Consulting Fee-Merck and Company, Inc.|Consulting Fee-Takeda Pharmaceuticals, Inc.-Other_Role-Consultant |Consulting Fee-Eli Lilly and Company-Other_Role-consultant|Consulting Fee-Genentech, Inc.-Other_Role-Consultant|Contracted Research-Boehringer Ingelheim Vetmedica GmbH-Principal_Investigator|Consulting Fee-Celgene|Contracted Research-Celgene - 09/20/2018


Dr. Levy is Associate Professor at the Johns Hopkins School of Medicine and recently recruited to be Clinical Director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington DC. Prior to his Hopkins appointment, Dr Levy was Medical Director of Thoracic Oncology Program for Mount Sinai Health Systems in New York City and Associate Director of the Cancer Clinical Trials Office (CCTO). Dr Levy is a physician scientist who is currently leading global immunotherapy trials evaluating checkpoint point inhibitors with novel combination strategies. In addition, he currently leads multiple targeted therapy trial with specific interest in EGFR mutations. Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as editor in chief for the ASCO Self Evaluation Program (SEP). He also serves on the Lungevity Scientific Advisory board as well as the IASLC’s International Lung Cancer Foundation Advisory Board. He is an ad hoc reviewer for Clinical Cancer Research (CCR), Annals of Oncology and the Journal of Clinical Oncology. He was recently selected as one of only 15 oncologist in the country to the prestigious ASCO Leadership Development Program whose mission is to identify and develop future leaders of ASCO.

C:\Users\vwasta1\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Word\LEVY_BEN_Cropped.jpeg